Ponatinib
FLT3-Mutated High-Risk Myelodysplastic Syndrome
OHSU Knight Cancer InstituteSmall moleculePhase 1/2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
315 Active assets in the FLT3-Mutated High-Risk Myelodysplastic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Sawa Ito, MD | Phase 4 | BB |
Anti-Thymoglobulin, Rabbit Peking University First Hospital | Phase 2/3 | BB |
Cytosin-Arabinosid The First Affiliated Hospital of Soochow University | Phase 4 | BB |
FILGRASTIM City of Hope Medical Center | Phase 4 | BB |
Daunorubicin OHSU Knight Cancer Institute | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Ponatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
65 / 100
View asset →blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
65 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →